Pubdate: Sun, 28 Mar 2010
Source: Times Union (Albany, NY)
Copyright: 2010 Capital Newspapers Division of The Hearst Corporation
Contact: http://www.timesunion.com/forms/emaileditor.asp
Website: http://www.timesunion.com/
Details: http://www.mapinc.org/media/452
Author: Michael Brannigan
Note: Michael Brannigan is the Pfaff Endowed Chair in Ethics and 
Moral Values at The College of Saint Rose.

LET THE SICK DECIDE IF MARIJUANA IS MEDICINE

Pain can saturate one's entire being. This hit home recently when my
mother endured bouts of chemotherapy for stomach cancer. Drugs to
relieve her relentless nausea offered little benefit. As with
countless other patients, her medicine made matters worse.

For patients in intractable pain, time is not on their side.
Therefore, for supporters, New York's pending legalization of the
medical provision and use of marijuana is timely. Meanwhile, the
debate continues.

Good ethics requires good facts, as in accurate, relevant and
evidence-based. Clearly, cannabis' history of illegal use and
association with lethal drugs has overshadowed its supposed
therapeutic value in alleviating chemotherapy-induced nausea, reducing
glaucoma's intraocular pressure, mitigating AIDS symptoms and
relieving chronic pain. Furthermore, its psychoactive component spawns
fears of dependency and abuse, although authorized stimulants,
antidepressants and analgesics also produce highs and lows.

While critics allege medical marijuana to be addictive, a so-called
gateway to lethal drugs and without medical benefit, they also reject
it as valid medicine. So, is medical marijuana "real medicine" or an
oxymoron?

This deep-seated question is unsettling.

Why? Because it unearths an unhealthy tension among politics, power
and science.

In his "Social Transformation of American Medicine," sociologist Paul
Starr chronicles this tension by describing how U.S. mainstream
medicine, through licensing and certification requirements, assumed a
purportedly more "scientific" medical paradigm that marginalized
alternative, including herbal, therapies.

Wedded politics and science then enabled federal agencies' virtual
embargo on serious research into marijuana's therapeutic efficacy. To
illustrate, the National Institute on Drug Abuse plantation at the
University of Mississippi is the only place where researchers can
legally obtain marijuana. Yet, with pressure from the Drug Enforcement
Agency, NIDA's ongoing denial of research on the plant's medical
benefits has blocked important clinical studies.

As Madelon Lubin Finkel, clinical public health professor at Cornell's
Weill Medical College asserts, "reasons for this prohibition are
clearly politically ideological."

Politics' power over science is especially apparent since the biggest
stakeholder in defining "real medicine" is the pharmaceutical
industry, "Big Pharma." Generous government funding for research into
a synthetic substitute for tetrahydrocannabinol, the primary
psychoactive chemical in marijuana, led to the 1985 FDA approval of
Marinol(r), a prescription drug for chemotherapy-related nausea and
AIDS patients' weight loss. Touted as safer and more effective than
natural botanical marijuana, Marinol, as "real medicine," may have
diverted research from the therapeutic potential of the plant itself.

Since good ethics requires good facts, without sufficient comparative
clinical studies, findings become arbitrary. Is a synthetic substitute
better than nature's botanical remedy?

In their book "Dying to Get High," sociologist Wendy Chapkis and
communications expert Richard Webb argue that "pharmaceutical purity"
is a misleading notion given the rubric of side effects for most
prescription drugs, ranging from organ damage to heart failure to
nausea to depression to suicidal tendencies. At $30 a pill, Marinol is
a costly trade-off for the patient, but profitable in one of the most
lucrative industries in the United States, Big Pharma.

The moral center of concern in health care should be the patient. When
that center shifts to political ideology, we abdicate moral
accountability to our patients.

Will legalizing medical marijuana help restore accountability?

Although the jury is still out regarding side effects, the Institute
of Medicine's 1999 report "Medicine and Marijuana" finds "no
conclusive evidence that the drug effects of marijuana are causally
linked to the subsequent abuse of other illicit drugs." Moreover, the
Drug Policy Education Group's 2002 account (http://tinyurl.com/yct223a)
refutes DEA arguments regarding marijuana's harms.

We can bestow dignity on patients by empowering them to make their own
informed choices among reasonable options. As to these options, good
science and sound moral principles -- not political ideology or
industry profit -- should help determine how we characterize "real
medicine."
- ---
MAP posted-by: Richard Lake